Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-04-17 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Regulatory Filings
2025-04-17 Chinese
2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与实际使用情况的专项报告" which translates to "2024 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the company's fundraising activities, the amount raised, the management and use of these funds, and includes verification and audit opinions from an accounting firm. The content focuses on the use and management of capital raised through stock issuance, including specific projects funded, cash management of idle funds, and compliance with regulatory requirements. This is a specialized report on capital raising and fund usage rather than a general annual report or earnings release. It is not a simple announcement or a proxy statement but a detailed report on capital/financing activities. Therefore, the document fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising, financing activities, or capital structure changes. The document length (5673 characters) and detailed financial data support this classification with high confidence.
2025-04-17 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2024. It contains detailed financial data including assets, net profit, earnings per share, shareholder structure, and business operations. It also includes audit information with a standard unqualified opinion from an accounting firm, and detailed company business descriptions and management assurances. The length of the document (6642 characters) and the presence of substantive financial data and analysis confirm it is a full annual report rather than a brief announcement or summary notice. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-17 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2024' which translates to 'Annual Report 2024'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholding changes, financing and profit distribution, board and senior management information, industry information, corporate governance, and financial accounting reports. It includes audited financial data, management discussion, risk factors, and detailed financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The presence of an auditor's unqualified opinion and detailed financial tables further confirms this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-17 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by 安徽峆一药业股份有限公司. It details the nature of the accounting policy changes, the dates of implementation, the reasons and rationality behind the changes, and the approvals by the board, supervisory committee, and audit committee. It does not contain full financial statements or comprehensive financial performance data. The document is relatively short (1705 characters) and serves as a formal announcement of the accounting policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2025-04-17 Chinese
关联交易公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction involving the company and its related entities. It details the transaction overview, decision and approval process, related party information, pricing policy, and the impact on the company. There is no financial statement or comprehensive financial report included. The document is a formal disclosure of a related party transaction, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Interim Report, or Capital Update.
2025-04-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.